Tumor response dynamics of advanced non-small-cell lung cancer patients treated with PD-1 inhibitors: Imaging markers for treatment outcome

摘要: Purpose: We evaluated tumor burden dynamics in patients with advanced non-small cell lung cancer (NSCLC) treated commercial PD-1 inhibitors to identify imaging markers associated improved overall survival (OS).Experimental Design: The study included 160 NSCLC nivolumab or pembrolizumab monotherapy as a part of clinical care. Tumor were studied for the association OS.Results: change at best response (BOR) ranged from -100% +278% (median, +3.5%). Response rate (RR) was 18% (29/160). Current and former smokers had higher RR than never (P = 0.04). Durable disease control least 6 months noted 26 (16%), which 10 stable BOR. Using landmark analysis, <20% increase baseline within 8 weeks therapy longer OS ≥20% (median OS, 12.4 vs. 4.6 months, P < 0.001). Patients throughout significantly reduced hazards death (HR, 0.24; Cox 0.0001) after adjusting smoking 0.86; 0.61) 1.55; 0.062), even though some met criteria RECIST progression while on therapy. One patient (0.6%) atypical pattern consistent pseudoprogression.Conclusions: Objective durable 24% inhibitors. A during proposing practical marker treatment benefit. Pseudoprogression is rare NSCLCs Clin Cancer Res; 23(19); 5737-44. ©2017 AACR.